Related Experiment Videos
Supplemental peripheral blood stem cells to decrease marrow rejection in adult patients with severe aplastic anemia.
Chang-Ki Min1, Dong Wook Kim, Jong Wook Lee
1The Catholic Hemopoietic Stem Cell Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea. ckmin@cmc.cuk.ac.kr
American Journal of Hematology
|February 9, 2002
Summary
This study shows that combining CD34-enriched stem cells with fresh marrow is a feasible transplant strategy for severe aplastic anemia (SAA) patients, achieving good survival rates with manageable graft-versus-host disease (GVHD).
Area of Science:
- Hematology
- Transplantation Immunology
- Stem Cell Biology
Background:
- Severe aplastic anemia (SAA) is a life-threatening condition requiring effective treatment strategies.
- Multi-transfused SAA patients often develop alloimmunization, complicating stem cell transplantation.
- Standard conditioning regimens may have significant toxicities.
Purpose of the Study:
- To evaluate the efficacy and safety of a novel stem cell transplant approach for multi-transfused SAA patients.
- To assess engraftment, graft-versus-host disease (GVHD), and survival outcomes.
- To determine the feasibility of using CD34-selected peripheral blood stem cells (PBSC) combined with unmanipulated bone marrow.
Main Methods:
- Twenty-two multi-transfused SAA patients received transplants using cyclophosphamide (CY), antithymocyte globulin, procarbazine, CD34(+)-enriched PBSC, and fresh marrow.
- T-cell depletion of PBSC was performed via immunoadsorption or magnetic cell sorting.
- Engraftment, GVHD incidence, survival, and causes of mortality were monitored.
Main Results:
- Successful engraftment was achieved in most patients, with median times to neutrophil and platelet recovery of 12 and 17 days, respectively.
- Graft failure occurred in two patients but was successfully treated with unpurged PBSC.
- Acute GVHD grade II occurred in 4 patients; no grade III/IV acute GVHD was observed. Chronic GVHD occurred in 4/21 evaluable patients.
- The overall survival rate was 83.9% with a median follow-up of 33.5 months.
- Three patients died due to treatment-related complications (heart failure, extensive chronic GVHD, sepsis).
Conclusions:
- CD34-enriched PBSC combined with unmanipulated marrow may overcome histocompatibility antigen sensitization in SAA patients.
- This approach appears feasible for high-risk adult SAA patients, with a reduced risk of severe GVHD.
- The observed survival rate suggests this modified stem cell transplantation strategy is promising for SAA treatment.